Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy volunteers (HV)
and in patients with paroxysmal nocturnal hemoglobinuria (PNH).